targeted sequencing

Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.

ArcherDx will develop in vitro diagnostic tests, including companion diagnostics, to run on Illumina's NextSeq 550Dx next-generation sequencing system.

The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.

Circulating tumor DNA detection in stage III colon cancer patients after surgery and adjuvant chemotherapy coincided with a rise in recurrence risk.

Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.

The in vitro diagnostic uses next-generation sequencing to detect clinically actionable genetic variants to guide therapy selection for cancer patients.

The company is commercializing a method developed by researchers at Johns Hopkins that detects cancer with high specificity from a blood sample.

The firm is conducting validation studies on its lung cancer test and continues to anticipate commercializing it in the second half of this year.